Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.58 |
| ▸ | MGLL | Q99685 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279698 | 0.88 | HPGD (0.71) | HSD11B1MGLLHPGDPKMLRRK2 | |
| SCHEMBL2653348 | 0.86 | HPGD (0.73) | HSD11B1HPGDPKMMAPTMEN1 | |
| SCHEMBL2075037 | 0.86 | HPGD (0.68) | HSD11B1MGLLHPGDPKMMAPT | |
| SCHEMBL22406684 | 0.83 | HPGD (0.55) | HSD11B1MGLLHPGDPKMMEN1 | |
| SCHEMBL5630460 | 0.82 | HPGD (0.54) | HSD11B1MGLLHPGDPKMMEN1 | |
| SCHEMBL5799486 | 0.81 | HSD11B1 (0.51) | HSD11B1MGLLHPGDFAAHTSHR | |
| SCHEMBL17615014 | 0.78 | HSD11B1 (0.51) | HSD11B1MGLLHPGDPKMMAPT | |
| Methane SCHEMBL7459255 | 0.78 | HTR1A (0.57) | — | |
| SCHEMBL6985467 | 0.77 | HTR1A (0.55) | — | |
| SCHEMBL19971721 | 0.77 | HTR1A (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118507-A1 | Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4--Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives | PIERRE FABRE MEDICAMENT (FR) | 2009-05-07 | — | — | US | disclosed |
| CN-1160348-C | Aryl-{4-fluoro-4-[(2-pyridin-2-YL-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-HT1 receptor antagonists | Ƥ����������ҩƷ��˾ | 2004-08-04 | — | — | CN | disclosed |
| CN-1325396-A | Aryl-{4-fluoro-4-[(2-pyridin-2-YL-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-HT1 receptor antagonists | PF MEDICAMENT (FR) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118507-A1 | Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4--Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives | DNMT1, MCM4, MCM5 | HSD11B1 3112/4885MGLL 4350/4885HPGD 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.